Ocugen Inc.

08/26/2024 | Press release | Distributed by Public on 08/26/2024 05:12

Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.